Serum Institute of India cleared the air on concerns expressed over the supposedly high market price for its Covishield vaccine, saying the comparison being done between global prices of the coronavirus vaccine with India is inaccurate.
Serum, which produces the Oxford-AstraZeneca vaccine at its Pune facility, said that initial prices were kept very low globally as it was based on advance funding given by some countries for vaccine manufacturing.
"The initial supply price of Covishield for all government immunisation programme, inculding India has been the lowest," the company has said on Saturday.
Serum said it would price its vaccine Covishield at Rs 400 per dose for state governments and Rs 600 per dose for private hospitals as India opens up Covid-19 vaccinations for all citizens over 18 from May 1. Serum charges the central government Rs 150 per dose for the existing supplies.
Addressing the ongoing public scepticism towards the pricing of Covishield, the company said in light of the current dire situation it has to ensure sustainability and must be able to invest in scaling up and expanding the production capacity.
"Only a limited proportion of Serum's volume will be sold to private hospitals at Rs 600 per dose.
The price of the vaccine is still far lower than other medical treatments and essentials required to treat coronavirus infection and other life-threatening diseases," the company said in a statement.
"Covisheld is the most affordable vaccine against coronavirus available in the market today," it said.
We at @SerumInstIndia have for the past five decades been at the forefront of supplying vaccines and saving lives globally. We care about and respect every human life and strongly believe in transparency, and thus we hope our statement below can clear any confusions. pic.twitter.com/YQ3x38BuFL
— SerumInstituteIndia (@SerumInstIndia) April 24, 2021
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU